Novel, semi-automated, 60-min-assay to determine von Willebrand factor cleaving activity of ADAMTS-13

Thrombosis Research

Volumn 118, Issue 6, 2006, Pages 723-731

  Kostousov, Vadim ^a,b   Fehr, Jörg ^a,b   Bombeli, Thomas ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BARIUM CHLORIDE; BUFFER; DILUENT; RISTOCETIN; UREA; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACCURACY; ARTICLE; CALIBRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DILUTION; ELECTROPHORESIS; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERTHERMIC THERAPY; INCUBATION TIME; PLASMA; PRIORITY JOURNAL; ROOM TEMPERATURE; SENSITIVITY ANALYSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; AUTOMATION; BIOLOGICAL ASSAY; CLINICAL LABORATORY TECHNIQUES; HUMANS; MASS SCREENING; PURPURA, THROMBOTIC THROMBOCYTOPENIC; SENSITIVITY AND SPECIFICITY; TIME FACTORS; VON WILLEBRAND FACTOR;

EID: 33750428228     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.12.006     Document Type: Article

References (22)

1. Bianchi V., Robles R., Alberio L., Furlan M., and Lammle B. Von Willebrand, factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 100 (2002) 710-713
2. Tsai H.M., Li A., and Rock G. Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. Clin Lab 47 (2001) 387-392
3. Chang J.C. The understanding of thrombotic thrombocytopenic purpura: dyadic, triadic, pentadic, and other manifestations. J Clin Apheresis 19 (2004) 2-4
4. Vuylsteke P., Knockaert D.C., Blockmans D., Arnout J., and Vanderschueren S. Abdominal pain, hypertension, and thrombocytopenia. Lancet 362 (2003) 1720
5. Kunze A., Terborg C., Gerth J., Heide G., and Witte O.W. Thrombotisch-thrombozytopenische Purpura Verminderte Aktivität der von-Willebrand-Faktor-spaltenden Protease. Nervenarzt 75 (2004) 785-789
6. Overman M., and Brass E. Worsening of thrombotic thrombocytopenic purpura symptoms associated with desmopressin administration. Thromb Haemost 92 (2004) 886-887
7. Furlan M., and Lammle B. Assays of von Willebrand factor-cleaving protease: a test for diagnosis of familial and acquired thrombotic thrombocytopenic purpura. Semin Thromb Hemost 28 (2002) 167-172
8. Veyradier A., and Girma J.P. Assays of ADAMTS-13 activity. Semin Hematol 41 1 (2004) 41-47
9. Bohm M., Vigh T., and Scharrer I. Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13). Ann Hematol 81 (2002) 430-435
10. Tripodi A., Chantarangkul V., Bohm M., Budde U., Dong J.F., Friedman K.D., et al. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost 2 (2004) 1601-1609
11. Kessler C.M. An introduction to factor VIII inhibitors: the detection and quantitation. Am J Med 91 5A (1991) 1S-5S
12. Tsai H.M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 87 10 (May 15 1996) 4235-4244
13. Perutelli P., Amato S., and Molinari A. Von Willebrand factor cleavage in vitro at room temperature occurs without the need for divalent ions. Pathophysiol Haemost Thromb 33 suppl 2 (2003) FP15 [abst.]
14. Obert B., Tout H., Veyradier A., Fressinaud E., Meyer D., and Girma J.P. Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF. Thromb Haemost 82 (1999) 1382-1385
15. Whitelock J.L., Nolasco L., Bernardo A., Moake J., Dong J.F., and Cruz M.A. ADAMTS-13 activity in plasma is rapidly measured by a new ELISA method that uses recombinant VWF-A2 domain as substrate. J Thromb Haemost 2 (2004) 485-491
16. Bohm M., Gerlach R., Beecken W.D., Scheuer T., Stier-Bruck I., and Scharrer I. ADAMTS-13 activity in patients with brain and prostate tumors is mildly reduced, but not correlated to stage of malignancy and metastasis. Thromb Res 111 (2003) 33-37
17. Zhou W., and Tsai H.M. An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutations. Thromb Haemost 91 (2004) 806-811
18. Furlan M., Robles R., Solenthaler M., Wassmer M., Sandoz P., and Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 89 (1997) 3097-3103
19. Gerritsen H.E., Turecek P.L., Schwarz H.P., Lammle B., and Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 82 (1999) 1386-1389
20. Tsai H.M., and Lian E.C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339 (1998) 1585-1594
21. Schneppenheim R., Budde U., Hassenpflug W., and Obser T. Severe ADAMTS-13 deficiency in childhood. Semin Hematol 41 (2004) 83-89
22. Perez Sanchez P., and Aguilera L. Plaquetopenia preoperatoria con diagnóstico postoperatorio de púrpura trombocitopénica trombótica. Rev Esp Anestesiol Reanim 47 (2000) 417-421